Background: Comparison of the efficacy and adverse reactions of anlotinib and nanoparticle albumin-boundpaclitaxel (Nab-P) in the treatment of third-line and above extensive-stage small cell lung cancer (ES-SCLC).
Methods: In this study, we retrospectively analyzed the effectiveness and safety of anlotinib and Nab-P in clinical practice. We enrolled 71 patients with ES-SCLC who received anlotinib monotherapy or Nab-P monotherapy as third-line or later-line therapy. Divided into Anlotinib group (n=35) and Nab-P group (n=36). We analyzed progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), and adverse events (AE) in the two groups.
Results: Among all patients, the Nab-P group showed better overall response rate (ORR) compared with the Anlotinib group [19.4% vs. 8.6%, P = 0.193]. There was no significant difference in PFS and OS between the two groups. The most common AEs in the Anlotinib group were liver damage, fatigue, hypertension, and hand-foot syndrome. The most common AEs in the Nab-P group were liver damage, neutropenia, fatigue, and muscle aches. There were no treatment-related deaths.
Conclusions: In our real-world data analysis, patients treated with Nab-P had a better overall response rate (ORR), but no benefit of PFS or OS. Both treatment options are effective, so the choice should be based on their potential side effects.